|Bid||144.20 x 100|
|Ask||145.41 x 200|
|Day's Range||144.65 - 145.39|
|52 Week Range||120.75 - 150.28|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.07%|
In 1Q17, Bioverativ’s Eloctate witnessed revenues close to $155.9 million, which is about $48.0 million more YoY (year-over-year).
Abiomed (ABMD) reported a ~100% reorder rate in fiscal 4Q17, amounting to around $103.3 million, which was 34% higher on a YoY basis.
Growth stock ETFs can allow you to profit from rapidly-growing companies while diversifying your risk.